<DOC>
	<DOC>NCT02325674</DOC>
	<brief_summary>Post Authorisation Safety Registry for US patients with Generalised Lipodystrophy treated with Metreleptin</brief_summary>
	<brief_title>Post Authorisation Safety Registry for US Patients With Generalised Lipodystrophy Treated With Metreleptin</brief_title>
	<detailed_description>Post Authorisation Safety Registry for US patients with Generalised Lipodystrophy treated with Metreleptin. This registry will add to the knowledge about metreleptin gained from clinical trials by providing information on the incidence rates of acute pancreatitis, hypoglycemia, hypersensitivity and lymphoma in patients treated with metreleptin in routine clinical practice.</detailed_description>
	<mesh_term>Lipodystrophy</mesh_term>
	<mesh_term>Lipodystrophy, Congenital Generalized</mesh_term>
	<criteria>Patients who are treated with metreleptin as part of clinical care Patients who provide a written consent Patient receiving metreleptin as part of a clinical trial or through expended access including compassionate use Patients currently treated with an investigational agent as part of a clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Lipodystrophy</keyword>
	<keyword>Metreleptin Registry</keyword>
</DOC>